INLEXZO received permanent billing code highlighting access for patients with certain bladder cancers

Johnson & Johnson has recently announced the permanent Healthcare Common Procedure Coding System J-code for INLEXZO is now in effect. Adult patients living with certain types of Bacillus Calmette-Guérin -unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors who have historically had limited options before possible bladder removal may benefit from a more standardized billing pathway for this therapy.

“Navigating reimbursement complexity shouldn’t stand between patients and a therapy that could change their disease trajectory,” said Scott White, Chief Operating Officer, North America, Johnson & Johnson. “This permanent code allows healthcare providers to focus on delivering innovative care by helping reduce administrative complexity associated with billing.”

Note that INLEXZO was recently approved by the FDA in September 2025 for the treatment of adult patients with BCG-unresponsive, NMIBC with carcinoma in situ, with or without papillary tumors. It is the first and only FDA-approved intravesical drug-releasing system to provide extended local delivery of a cancer medication into the bladder.

“Patients often experience fear and frustration when treatments are available but inaccessible due to reimbursement delays,” said Aleksandar Alchev*, DMD, MBA, Director, Business Development, Minnesota Urology. “INLEXZO’s permanent J-code may help support more consistent billing processes and may help facilitate the treatment process for patients over time.”

“For two decades, BCAN has been guided by the voices and experiences of people impacted by bladder cancer. New treatment options, including those with permanent billing codes, are welcome news for patients and their loved ones. They deserve access to therapies without unnecessary delays due to administrative steps,” said Meri-Margaret Deoudes**, CEO, Bladder Cancer Advocacy Network (BCAN).

---

---

Related Topics and Keywords

bladder cancer, INLEXZO, Johnson and Johnson